RAC3 and lung adenocarcinoma: The results show that RAC3 knockout A549-PR cells have increased sensitivity to paclitaxel, and the resistance of paclitaxel-sensitive lung adenocarcinoma cells to paclitaxel can be explained by the overexpression of RAC3. We concluded that RAC3 expression in A549-PR cells is associated with paclitaxel resistance.